# Bill Maris

> Bill Maris is a Series C investor at S32 (San Diego) backing Health Care and Biotechnology. See 24 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [S32](https://shizune.co/investors/profile/section-32)
- Location: San Diego, United States
- Total investments: 24
- Last investment: Feb 2024
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bmaris
- X (Twitter): http://twitter.com/billmaris

Bill Maris is a Series C investor at S32 in San Diego focused on Health Care and Biotechnology. Bill Maris was the Founder and CEO of GV and attended Middlebury College.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 21% |
| Biotechnology | 4 | 17% |
| Information Technology | 3 | 13% |
| SaaS | 2 | 8% |
| Genetics | 2 | 8% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 21% |
| Series D | 4 | 17% |
| Seed | 3 | 13% |
| Series E | 3 | 13% |
| Series A | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 42% |
| United Kingdom | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M | Series E | Feb 15, 2024 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M |  | Feb 15, 2024 |  |
| Metaphysic | Metaphysic is a creator of a program for creating synthetic media that aims to advance the limits of human expression through ethical use.The company's software reconstructs low-resolution film, makes natural-looking facial representations, enables editing of expressions, facial characteristics, or full faces, and reconstructs low-resolutionfootage, enabling content makers to use artificial intelligence in their work. | $7.5M | Seed | Jan 25, 2022 |  |
| Dialpad | Dialpad is the leading AI-powered communications and agentic platform that turns conversations into opportunities and helps teams make smart calls. The communications and contact center provider offers native, real-time transcription, automated note-taking, live sentiment, and voice analytics to market, and with the rising demand for remotecollaboration. It offers Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center solutions that are all powered by VoiceAI. These products cover the full range of modern business communications needs with a range of system software that offers voice, video, group messaging, SMS, MMS, conferencing, screen sharing, and document sharing services that enable employees to collaborate securely from anywhere across any device, in a single platform. | $170M | Series F | Dec 16, 2021 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $300M | Series D | Dec 07, 2021 |  |
| Dialpad | Dialpad is the leading AI-powered communications and agentic platform that turns conversations into opportunities and helps teams make smart calls. The communications and contact center provider offers native, real-time transcription, automated note-taking, live sentiment, and voice analytics to market, and with the rising demand for remotecollaboration. It offers Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center solutions that are all powered by VoiceAI. These products cover the full range of modern business communications needs with a range of system software that offers voice, video, group messaging, SMS, MMS, conferencing, screen sharing, and document sharing services that enable employees to collaborate securely from anywhere across any device, in a single platform. | $100M | Series E | Oct 06, 2020 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $270M | Series C | Aug 26, 2020 |  |
| Legacy | Legacy provides a service for at-home sperm testing and cryopreservation, allowing individuals to take control of their fertility health from the comfort of their homes. Their semen analysis is conducted in CLIA-certified labs, ensuring high-quality testing without the need for direct doctor involvement. As America's largest at-home fertilityclinic for men, Legacy empowers clients to understand their reproductive health and plan for the future effectively. | $3.5M | Seed | Jan 31, 2020 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $160M | Series B | Jul 24, 2019 |  |
| Embark | Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on themarket. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care. | $12M | Series A | Apr 11, 2019 |  |

10 of 24 investments shown.

## Co-investors
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 7 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together
- [Sands Capital Ventures](https://shizune.co/investors/profile/sands-capital-ventures) — VC Fund, 5 deals together
- [Amasia](https://shizune.co/investors/profile/amasia) — VC Fund, 4 deals together
- [Artis Ventures](https://shizune.co/investors/profile/artis) — VC Fund, 4 deals together

## About S32

VC Fund · San Diego, United States

S32 the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe.Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments.The fund will be run directly by Maris and primarily based out of SanDiego.

5 contacts available at S32.

| Name | Title | Profile |
| --- | --- | --- |
| Andrew Harrison | Managing Partner and CEO | https://shizune.co/investors/profile/andrew-harrison-b3e0 |
| Bill Maris | Founder | https://shizune.co/investors/profile/bill-maris |
| Jennifer Kercher | COO and General Counsel | https://shizune.co/investors/profile/jennifer-kercher |
| Jonathan Faerber | CFO | https://shizune.co/investors/profile/jonathan-faerber |
| Lindsey Acharya | Chief of Staff and Executive Assistant | https://shizune.co/investors/profile/lindsey-acharya |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Bill Maris invest in?

Bill Maris invests primarily in Health Care, Biotechnology and Information Technology startups, most often at Series C and Series D stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bill Maris last invest?

The most recent investment recorded for Bill Maris closed in Feb 2024. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co